Alecensa

Chemical Namealectinib
Dosage FormCapsule (oral; 150 mg)
Drug ClassKinase inhibitors
SystemRespiratory
CompanyHoffmann-La Roche
Approval Year2015

Indication

  • For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).
Last updated on 10/19/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Alecensa (alectinib) Prescribing Information2018Genentech USA, Inc., a Member of the Roche Group, South San Francisco, CA